Wall Street analyst estimates for Pulmonx Corporation (LUNG): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.26 | ||
| 2026-07-29 | $-0.24 | $-0.28 | +14.3% |
| 2026-04-29 | $-0.33 | $-0.33 | +0.0% |
| 2026-03-04 | $-0.25 | $-0.39 | +35.9% |
| 2025-11-12 | $-0.34 | $-0.40 | +15.0% |
| 2025-07-30 | $-0.38 | $-0.40 | +5.0% |
| 2025-04-30 | $-0.36 | $-0.37 | +2.7% |
| 2025-02-19 | $-0.33 | $-0.45 | +26.7% |
Valuation Ratios
| Price / Book | 2.28 |
| EV / EBITDA | -2.18 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.0M | $32.6M | $32.7M | $48.4M | $53.7M | $68.7M | $83.8M | $90.5M |
| Cost of Revenue | $7.7M | $10.2M | $11.5M | $12.8M | $13.8M | $17.9M | $21.8M | $23.4M |
| Gross Profit | $12.3M | $22.4M | $21.2M | $35.6M | $39.9M | $50.8M | $62.0M | $67.1M |
| Research & Development | $7.0M | $6.0M | $7.5M | $13.1M | $15.4M | $18.1M | $17.6M | $19.5M |
| Selling, General & Admin | $20.3M | $34.2M | $46.1M | $69.9M | $83.1M | $94.6M | $102.1M | $101.3M |
| Operating Expenses | $27.3M | $40.3M | $53.5M | $82.9M | $98.5M | $112.7M | $119.7M | $120.8M |
| Operating Income | -$15.1M | -$17.8M | -$32.3M | -$47.3M | -$58.6M | -$61.9M | -$57.7M | -$53.7M |
| EBITDA | -$15.7M | -$16.8M | -$28.4M | -$46.6M | -$56.0M | -$55.1M | -$50.8M | -$49.2M |
| Interest Expense | $2.5M | $2.3M | $3.2M | $829000 | $1.1M | $3.2M | $3.5M | $3.2M |
| Pre-tax Income | -$18.5M | -$20.3M | -$32.0M | -$48.3M | -$58.6M | -$60.3M | -$55.9M | -$53.4M |
| Income Tax | $12000 | $363000 | $213000 | $343000 | $353000 | $571000 | $500000 | $626000 |
| Net Income | -$18.5M | -$20.7M | -$32.2M | -$48.7M | -$58.9M | -$60.8M | -$56.4M | -$54.0M |
| EPS | $-0.89 | $-0.58 | $-0.90 | $-1.35 | $-1.59 | $-1.60 | $-1.44 | $-1.33 |
| EPS (Diluted) | $-0.89 | $-0.58 | $-0.90 | $-1.35 | $-1.59 | $-1.60 | $-1.44 | $-1.33 |
| Shares Outstanding (Diluted) | $20.7M | $35.4M | $35.7M | $36.1M | $37.1M | $38.0M | $39.1M | $40.7M |
Price
| Price | $2.07 |
| Market Cap | $87M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACRV · ASRT · EDAP · HYPR · IMUX · PMVP · RLMD
Explore sector: Healthcare · Medical - Devices
More sections of LUNG: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks